Figure 7 shows the positive correlations of these drugs with LASP1, a promising therapeutic target in NSCLC due to its involvement in promoting tumor malignancy via the FAK-AKT pathway [33,34]. Here, PTK2 is linked to non-small cell lung carcinoma.